- Q1 2024 Bergenbio ASA Earnings Call TranscriptMay 29, 2024kr14.28 (-1.11%)Earnings
- Q3 2023 Bergenbio ASA Earnings Call TranscriptNov 14, 2023kr18.38 (+1.32%)Earnings
- Q2 2023 Bergenbio ASA Earnings Call TranscriptAug 23, 2023kr11.06 (-11.52%)Earnings
- Q4 2022 Bergenbio ASA Earnings Call TranscriptFeb 16, 2023kr625.94 (+2.84%)Earnings
- Q3 2022 Bergenbio ASA Earnings Call TranscriptNov 15, 2022kr661.34 (-1.73%)Earnings
- Q2 2022 Bergenbio ASA Earnings Call TranscriptAug 23, 2022kr1029.14 (-7.17%)Earnings
- Q1 2022 Bergenbio ASA Earnings Call TranscriptMay 24, 2022kr1342.54 (-5.76%)Earnings
- Bergenbio ASA Strategy Update TranscriptMay 04, 2022
- Q4 2021 Bergenbio ASA Earnings Call TranscriptFeb 16, 2022kr1486.73 (-4.44%)Earnings
- Q3 2021 Bergenbio ASA Earnings Call TranscriptNov 16, 2021kr1723.29 (-0.99%)Earnings
- Q2 2021 Bergenbio ASA Earnings Call TranscriptAug 17, 2021kr1944.31 (-3.68%)Earnings
- Q1 2021 Bergenbio ASA Earnings Call TranscriptMay 19, 2021kr2020.29 (-9.09%)Earnings
- Bergenbio ASA to Discuss Top Line Data From Phase II Trial Assessing Bemcentinib in Hospitalised COVID-19 Patients Call TranscriptMay 18, 2021
- Q4 2020 Bergenbio ASA Earnings Call TranscriptFeb 10, 2021kr2823.23 (-6.30%)Earnings
- Q3 2020 Bergenbio ASA Earnings Call TranscriptNov 17, 2020kr2413.12 (-3.95%)Earnings
- Q2 2020 Bergenbio ASA Earnings Call TranscriptAug 18, 2020kr3030.44 (-3.04%)Earnings
- Q1 2020 Bergenbio ASA Earnings Call TranscriptMay 19, 2020kr3436.22 (-7.01%)Earnings
- Q4 2019 Bergenbio ASA Earnings Call TranscriptFeb 11, 2020kr1653.92 (+11.37%)Earnings
Q1 2022 Bergenbio ASA Earnings Call Transcript
Ladies and gentlemen, welcome to the BerGenBio Q1 2022 Conference Call. (Operator Instructions) This conference is being recorded.
I will now hand it over to the speakers. Please begin.
Thank you very much for the introduction. Good morning. I'm Martin Olin, the CEO of BerGenBio. I'm very pleased to present to you with our Q1 highlights and financials for the first quarter. I'll just remind everyone about the forward-looking statements.
So this is a snapshot of BerGenBio. BerGenBio is a world leader in exploring (inaudible) transformative treatment modality for severe diseases. The development focus going forward will be focused on bemcentinib, our lead program, which has been dosed in more than 600 patients as of today, approximately 400 in oncology and 200 in COVID. And we are moving bemcentinib forward in 2 significant indications: One, a biomarker-driven population in first-line non-small cell lung cancer, which is carrying or harboring a mutation in the STK11 gene.
The second opportunity we're
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)